Merck Acts on its Post-Keytruda Plan, Spends $1.85B to Acquire Pandion for Autoimmune Therapies
Pandion’s short run as independent biotech is coming to an end. Almost two years after coming out of stealth mode, Merck and Co. is acquiring the company for its impressive …
Read More